Effects of PEG in patients with esophageal squamous cell carcinoma during concurrent chemoradiotherapy: a prospective study

被引:2
|
作者
Dong, Jie [1 ]
Dai, Zhenbo [2 ]
Cao, Fuliang [2 ]
Zhang, Wencheng [3 ]
Zhang, Tian [3 ]
Chen, Xi [3 ]
Chen, Yajun [1 ]
Zhao, Fangdong [3 ]
Li, Jiacheng [3 ]
Du, Qingwu [3 ]
Zhang, Kunning [3 ]
Zeng, Yaqi [1 ]
Li, Chunlei [1 ]
Wang, Yujie [1 ]
Li, Yueying [1 ]
Wang, Kun [1 ]
Pang, Qingsong [3 ,4 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Dept Nutr Therapy, Tianjin, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Dept Endoscopy Diag & Therapy, Tianjin, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Dept Radiat Oncol, Tianjin, Peoples R China
[4] Tianjin Med Univ Canc Inst & Hosp, Dept Radiat Oncol, Huanhu West Rd, Tianjin, Peoples R China
基金
中国国家自然科学基金;
关键词
PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; QUALITY-OF-LIFE; NECK-CANCER; ENTERAL NUTRITION; NASOGASTRIC TUBES; ESPEN GUIDELINES; HEAD; IMPACT; OBESITY; MALNUTRITION;
D O I
10.1016/j.gie.2023.04.2094
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims: This prospective study aimed to compare the changes in nutritional status and adverse events among patients with esophageal squamous cell carcinoma who received enteral nutrition through oral intake, PEG, and an enteral nasogastric tube (NGT) during concurrent chemoradiotherapy (CCRT). Methods: Of 141 included patients, 38, 74, and 29 patients were fed through oral intake, PEG, and NGTs, respectively. The clinical characteristics and baseline nutritional status of the 3 groups were recorded and analyzed. The Patient-Generated Subjective Global Assessment score, skeletal muscle index, and quality of life were evaluated before and after CCRT; the incidence of adverse events during feeding using PEG and NGTs was also recorded. The correlations among the different nutritional pathways and the CCRT-related adverse events (eg, radiation esophagitis and myelosuppression) were assessed. Results: At baseline, the oral intake group had a significantly better nutritional status and lower disease stage than those in the PEG and NGT groups. However, during CCRT, the oral intake group exhibited the most significant decreases in weight and skeletal muscle index. The synchronous chemotherapy completion rate was the highest in the PEG group. Multivariate analysis showed that the planning tumor volume and oral intake and NGT feeding pathways were associated with radiation esophagitis of at least grade 2. Conclusions: We found that PEG effectively maintained the body weight and skeletal muscle index of patients with esophageal cancer during CCRT. PEG also improved the synchronous chemotherapy completion rate and reduced the occurrence of at least grade 2 radiation esophagitis.
引用
收藏
页码:901 / +
页数:13
相关论文
共 50 条
  • [1] A prospective study of apatinib in combination with neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
    Wang, J.
    He, M.
    Yao, J.
    Cheng, Y.
    Wu, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S931 - S931
  • [2] Concurrent chemoradiotherapy for cervical esophageal squamous cell carcinoma: treatment results from a prospective observational study
    Li, H. -X.
    Liu, J.
    Cheng, Y.
    Liu, M. -N.
    Fang, W. -T.
    Lv, C. -X.
    DISEASES OF THE ESOPHAGUS, 2018, 31 (05) : 1 - 6
  • [3] Concurrent chemoradiotherapy alone is feasible for esophageal squamous cell carcinoma patients not suitable for surgery
    Chen, Yongshun
    Wang, Jun
    RADIOTHERAPY AND ONCOLOGY, 2018, 129 (01) : 182 - 182
  • [4] A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma
    Zhao, Chuanhua
    Lin, Li
    Liu, Jianzhi
    Liu, Rongrui
    Chen, Yuling
    Ge, Feijiao
    Jia, Ru
    Jin, Yang
    Wang, Yan
    Xu, Jianming
    ONCOTARGET, 2016, 7 (35) : 57310 - 57316
  • [5] Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma
    Qiu, Xiangnan
    Li, Jing
    Zhou, Han
    Zhang, Meng
    Jiang, Changchen
    Shen, Zetian
    Zhu, XiXu
    Li, Aomei
    Che, Yuxin
    Wu, Tiancong
    Wang, Zhen
    MEDICINE, 2020, 99 (04)
  • [6] A prospective phase II clinical study of concurrent chemoradiotherapy for 92 cases cervical esophageal squamous cell carcinoma.
    Li, Hongxuan
    Lv, Changxing
    Liu, Jun
    Fu, Xiaolong
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Nimotuzumab in combination with preoperative concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A prospective trial
    Wu, Xiaoyuan
    Chen, Yongshun
    Yang, Yuanyuan
    Hao, Daxuan
    Li, Xue
    He, Chunyu
    Liu, Jinsong
    Wang, Jianhua
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [8] Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study
    Zhai, Y.
    Hui, Z.
    Wang, J.
    Zou, S.
    Liang, J.
    Wang, X.
    Lv, J.
    Chen, B.
    Zhu, H.
    Wang, L.
    DISEASES OF THE ESOPHAGUS, 2013, 26 (05): : 503 - 509
  • [9] Prognosis and Benefit Factors of Definitive Concurrent Chemoradiotherapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma
    Shi, Z.
    Zhu, X.
    Ke, S.
    Qiu, H.
    Wang, J.
    Gong, Y.
    Shi, W.
    Chen, J.
    Zhao, W.
    Cai, G.
    Zhangcai, Y.
    Chen, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S121 - S121
  • [10] Is There a Benefit in Receiving Concurrent Chemoradiotherapy for Elderly Patients with Inoperable Thoracic Esophageal Squamous Cell Carcinoma?
    Zhang, Peng
    Xi, Mian
    Zhao, Lei
    Shen, Jing-Xian
    Li, Qiao-Qiao
    He, Li-Ru
    Liu, Shi-Liang
    Liu, Meng-Zhong
    PLOS ONE, 2014, 9 (08):